Communiqués Kyntra Bio, Inc.

Actions

KYNB

US31572Q8814

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/08/2026			Varia. 5j.	Varia. 1 janv.
7,070 ^USD	+1,43 %		+4,59 %	-19,48 %

07/07	Kyntra Bio, Inc. : Oppenheimer optimiste sur le dossier	ZM
11/06	Kyntra Bio présente de nouvelles données sur le roxadustat montrant une amélioration de l'indépendance transfusionnelle chez les patients souffrant d'anémie liée à des syndromes myélodysplasiques à faible risque	CI

Communiqués

06/08	Kyntra Bio to Report Second Quarter 2026 Financial Results	AQ
11/06	Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes	AQ
11/05	Kyntra Bio: Q1 Earnings Snapshot	AQ
11/05	Kyntra Bio : Reports First Quarter 2026 Financial Results	PU
11/05	Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
04/05	Kyntra Bio to Report First Quarter 2026 Financial Results	AQ
08/04	Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
16/03	Kyntra Bio : Reports Fourth Quarter 2025 Financial Results	PU
16/03	Kyntra Bio: Q4 Earnings Snapshot	AQ
16/03	Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
11/03	Kyntra Bio : Corporate Presentation – March 2026	PU
09/03	Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results	AQ
26/02	Kyntra Bio : Corporate Presentation – February 2026	PU
23/02	Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026	AQ
17/02	Kyntra Bio to Participate in Upcoming Investor Conferences	AQ
20/01	Kyntra Bio : FibroGen, Inc. Corporate Presentation – January 2026	PU
08/01	FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum	AQ
07/01	FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum	AQ
15/12	Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration	AQ
02/12	FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit	AQ
10/11	FibroGen : Reports Third Quarter 2025 Financial Results	PU
10/11	FibroGen: Q3 Earnings Snapshot	AQ
10/11	FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
03/11	FibroGen to Report Third Quarter 2025 Financial Results	AQ
24/09/25	FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer	AQ